Building the foundation for genomics in precision medicine

Precision medicine has the potential to profoundly improve the practice of medicine. However, the advances required will take time to implement. Genetics is already being used to direct clinical decision-making and its contribution is likely to increase. To accelerate these advances, fundamental changes are needed in the infrastructure and mechanisms for data collection, storage and sharing. This will create a continuously learning health-care system with seamless cycling between clinical care and research. Patients must be educated about the benefits of sharing data. The building blocks for such a system are already forming and they will accelerate the adoption of precision medicine.

[1]  Rosalind Eeles,et al.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. , 2010, JAMA.

[2]  S. Miller,et al.  Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality , 2012 .

[3]  Matthew S. Lebo,et al.  Canadian Open Genetics Repository (COGR): a unified clinical genomics database as a community resource for standardising and sharing genetic interpretations , 2015, Journal of Medical Genetics.

[4]  Gustavo Stolovitzky,et al.  The Prostate Cancer DREAM Challenge: A Community-Wide Effort to Use Open Clinical Trial Data for the Quantitative Prediction of Outcomes in Metastatic Prostate Cancer. , 2015, The oncologist.

[5]  Masato Kimura,et al.  NCBI’s Database of Genotypes and Phenotypes: dbGaP , 2013, Nucleic Acids Res..

[6]  C. Morel,et al.  The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease. , 2009, Expert opinion on biological therapy.

[7]  angesichts der Corona-Pandemie,et al.  UPDATE , 1973, The Lancet.

[8]  Eric Boerwinkle,et al.  In silico tools for splicing defect prediction - A survey from the viewpoint of end-users , 2013, Genetics in Medicine.

[9]  Garry R. Cutting,et al.  Cystic fibrosis genetics: from molecular understanding to clinical application , 2014, Nature Reviews Genetics.

[10]  Randy L. Gollub,et al.  High Throughput Tools to Access Images from Clinical Archives for Research , 2014, Journal of Digital Imaging.

[11]  Murray Grossman,et al.  A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank , 2014, Alzheimer's & Dementia.

[12]  Orion J. Buske,et al.  The Matchmaker Exchange: A Platform for Rare Disease Gene Discovery , 2015, Human mutation.

[13]  K. A. Gelmon.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .

[14]  Elaine Lyon,et al.  The GeneInsight suite: a platform to support laboratory and provider use of DNA‐based genetic testing , 2011, Human mutation.

[15]  Elizabeth W Karlson,et al.  Biobank participants' preferences for disclosure of genetic research results: perspectives from the OurGenes, OurHealth, OurCommunity project. , 2014, Mayo Clinic proceedings.

[16]  Frederic D Bushman,et al.  Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. , 2015, JAMA.

[17]  J. Shendure,et al.  A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.

[18]  C Béroud,et al.  UMD (Universal Mutation Database): A generic software to build and analyze locus‐specific databases , 2000, Human mutation.

[19]  Heidi L. Rehm,et al.  Communicating new knowledge on previously reported genetic variants , 2012, Genetics in Medicine.

[20]  Steven Van Vooren,et al.  Phenotypic information in genomic variant databases enhances clinical care and research: The international standards for cytogenomic arrays consortium experience , 2012, Human mutation.

[21]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[22]  Melissa A. Basford,et al.  The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future , 2013, Genetics in Medicine.

[23]  N. Paneth,et al.  Seven Questions for Personalized Medicine. , 2015, JAMA.

[24]  Justin Starren,et al.  Crossing the omic chasm: a time for omic ancillary systems. , 2013, JAMA.

[25]  P. Stenson,et al.  The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine , 2013, Human Genetics.

[26]  D. Altshuler,et al.  A map of human genome variation from population-scale sequencing , 2010, Nature.

[27]  Syed Haider,et al.  International Cancer Genome Consortium Data Portal—a one-stop shop for cancer genomics data , 2011, Database J. Biol. Databases Curation.

[28]  Rodney J Scott,et al.  Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database , 2013, Nature Genetics.

[29]  Fernando Martín-Sánchez,et al.  The use of self-quantification systems for personal health information: big data management activities and prospects , 2015, Health Information Science and Systems.

[30]  Richard L Schilsky,et al.  Building a rapid learning health care system for oncology: the regulatory framework of CancerLinQ. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Ibtisam Mahmoud,et al.  Framework for Responsible Sharing of Genomic and Health-Related Data , 2014 .

[32]  A. Metspalu,et al.  An epidemiological perspective of personalized medicine: the Estonian experience , 2015, Journal of internal medicine.

[33]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[34]  Guilherme Del Fiol,et al.  Integrating Genetic Information Resources with an EHR , 2006, AMIA.

[35]  Deanna M. Church,et al.  ClinVar: public archive of relationships among sequence variation and human phenotype , 2013, Nucleic Acids Res..

[36]  Mark Robson,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.

[37]  Mark A. Hoffman,et al.  Electronic medical records and personalized medicine , 2011, Human Genetics.

[38]  Heidi L Rehm,et al.  ClinGen--the Clinical Genome Resource. , 2015, The New England journal of medicine.

[39]  Sue Healey,et al.  ENIGMA—Evidence‐based network for the interpretation of germline mutant alleles: An international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes , 2012, Human mutation.

[40]  T E Klein,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing , 2011, Clinical pharmacology and therapy.

[41]  Manuel Corpas,et al.  DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources. , 2009, American journal of human genetics.

[42]  Chris Mungall,et al.  The Matchmaker Exchange API: Automating Patient Matching Through the Exchange of Structured Phenotypic and Genotypic Profiles , 2015, Human mutation.

[43]  T. Klein,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Abacavir Dosing: 2014 Update , 2014, Clinical pharmacology and therapeutics.

[44]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[45]  Wendy A. Wolf,et al.  The eMERGE Network: A consortium of biorepositories linked to electronic medical records data for conducting genomic studies , 2011, BMC Medical Genomics.

[46]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[47]  Heidi L Rehm,et al.  New approaches to molecular diagnosis. , 2013, JAMA.

[48]  E. Jameson,et al.  Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I. , 2013, The Cochrane database of systematic reviews.

[49]  Roy D. Sleator,et al.  'Big data', Hadoop and cloud computing in genomics , 2013, J. Biomed. Informatics.

[50]  M. Vihinen,et al.  Performance of mutation pathogenicity prediction methods on missense variants , 2011, Human mutation.

[51]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[52]  Abel N. Kho,et al.  Practical challenges in integrating genomic data into the electronic health record , 2013, Genetics in Medicine.

[53]  Shashikant Kulkarni,et al.  Assuring the quality of next-generation sequencing in clinical laboratory practice , 2012, Nature Biotechnology.

[54]  E. Jameson,et al.  Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I. , 2016, The Cochrane database of systematic reviews.

[55]  George P Patrinos,et al.  Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene , 2013, Nature Genetics.

[56]  Susan M. Jones,et al.  DREAMing of benchmarks , 2015, Nature Biotechnology.

[57]  T E Klein,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update , 2013, Clinical pharmacology and therapeutics.

[58]  Leslie G Biesecker,et al.  Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. , 2010, American journal of human genetics.